2月3日,路透社援引一位知情人士的消息报道,美国医疗器械制造商碧迪医疗(Becton Dickinson)正在考虑将其生命科学部门(包括诊断和生物科学两大业务板块)进行拆分,该部门的估值大约为300亿美元。据消息人士透露,碧迪医疗正在与顾问团队合作,探讨拆分该部门的可行性,目的是为了提高公司股价。预计最早可能在本周四的最新财报会议上,宣布这一涵盖生物科学和诊断解决方案的业务部门的拆分计划。英国《...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.